Article
Oncology
Harold Burstein, Angela R. DeMichele, Mark Somerfield, N. Lynn Henry
Summary: ASCO Rapid Recommendations Updates revise selected ASCO guideline recommendations in response to new and practice-changing data. These updates are based on evidence reviews and follow ASCO's Guideline Methodology Manual. The aim is to promptly disseminate updated recommendations to enhance cancer care decisions for healthcare professionals and the public.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Editorial Material
Oncology
Beverly Moy, R. Bryan Rumble, Lisa A. Carey
Summary: ASCO Rapid Recommendations Updates are revisions to specific ASCO guideline recommendations based on new and practice-changing data. These updates are supported by evidence review and follow ASCO's guideline development processes. The articles aim to disseminate updated recommendations in a timely manner to inform healthcare practitioners and the public about the best available cancer care options.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Beverly Moy, R. Bryan Rumble, Steven E. Come, Nancy E. Davidson, Angelo Di Leo, Julie R. Gralow, Gabriel N. Hortobagyi, Douglas Yee, Ian E. Smith, Mariana Chavez-MacGregor, Rita Nanda, Heather L. McArthur, Laura Spring, Katherine E. Reeder-Hayes, Kathryn J. Ruddy, Paul S. Unger, Shaveta Vinayak, William J. Irvin, Avan Armaghani, Michael A. Danso, Natalie Dickson, Sophie S. Turner, Cheryl L. Perkins, Lisa A. Carey
Summary: This guideline provides recommendations on chemotherapy and targeted therapy for patients with HR-negative metastatic breast cancer, offering different treatment options based on patient's condition, such as combination chemotherapy, single-agent chemotherapy, or targeted therapy. Specific treatment options are also suggested for patients with different genetic mutations.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Beverly Moy, Bryan Rumble, Lisa A. Carey
Summary: ASCO Rapid Recommendations Updates aim to disseminate timely updated cancer care options to healthcare practitioners and the public.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Katherine S. Virgo, R. Bryan Rumble, Ronald de Wit, David S. Mendelson, Thomas J. Smith, Mary-Ellen Taplin, James L. Wade, Charles L. Bennett, Howard I. Scher, Paul L. Nguyen, Martin Gleave, Scott C. Morgan, Andrew Loblaw, Sean Sachdev, David L. Graham, Neha Vapiwala, Amy M. Sion, Virgil H. Simons, James Talcott
Summary: The updated ASCO guidelines recommend using Docetaxel, abiraterone, enzalutamide, or apalutamide in combination with androgen deprivation therapy (ADT) as standard care for noncastrate metastatic prostate cancer. In locally advanced nonmetastatic prostate cancer patients who have undergone radiotherapy, ADT combined with abiraterone and prednisolone is suggested. The guidelines also provide recommendations for management of biochemically recurrent nonmetastatic prostate cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
N. Lynn Henry, Mark R. Somerfield, Zoneddy Dayao, Anthony Elias, Kevin Kalinsky, Lisa M. McShane, Beverly Moy, Ben Ho Park, Kelly M. Shanahan, Priyanka Sharma, Rebecca Shatsky, Erica Stringer-Reasor, Melinda Telli, Nicholas C. Turner, Angela DeMichele
Summary: This study aims to update the biomarkers that guide systemic therapy for metastatic breast cancer (MBC). The authors conducted a systematic review and identified 19 studies, providing recommendations for testing and treatment. However, there is insufficient evidence for some tests' eligibility and monitoring methods.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Sharon H. Giordano, Rachel A. Freedman, Mark R. Somerfield
Summary: ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations in response to new and practice-changing data, aiming to disseminate updated recommendations in a timely manner to inform health practitioners and the public on the best available cancer care options.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Eric J. Roeland, Kari Bohlke, Vickie E. Baracos, Thomas J. Smith, Charles L. Loprinzi
Summary: ASCO Rapid Recommendations Updates revise guideline recommendations in response to new and practice-changing data, with the goal of providing the best available cancer care options to health practitioners and the public.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Rahul Seth, Sanjiv S. Agarwala, Hans Messersmith, Krishna C. Alluri, Paolo A. Ascierto, Michael B. Atkins, Kathryn Bollin, Matias Chacon, Nancy Davis, Mark B. Faries, Pauline Funchain, Jason S. Gold, Samantha Guild, David E. Gyorki, Varinder Kaur, Nikhil I. Khushalani, John M. Kirkwood, Jennifer Leigh McQuade, Michael O. Meyers, Anthony Provenzano, Caroline Robert, Mario Santinami, Amikar Sehdev, Vernon K. Sondak, Gilliosa Spurrier, Umang Swami, Thach-Giao Truong, Katy K. Tsai, Alexander van Akkooi, Jeffrey Weber
Summary: This study provides guidance to clinicians on the use of systemic therapy for melanoma. It presents updated recommendations based on a systematic review and identifies new potential treatment options for different stages and mutation statuses of melanoma.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Van K. Morris, Erin B. Kennedy, Nancy N. Baxter, Al B. Benson, Andrea Cercek, May Cho, Kristen K. Ciombor, Chiara Cremolini, Anjee Davis, Dustin A. Deming, Marwan G. Fakih, Sepideh Gholami, Theodore S. Hong, Ishmael Jaiyesimi, Kelsey Klute, Christopher Lieu, Hanna Sanoff, John H. Strickler, Sarah White, Jason A. Willis, Cathy Eng
Summary: The purpose of this study is to develop treatment recommendations for patients with metastatic colorectal cancer (mCRC). An Expert Panel convened by ASCO conducted a systematic review of relevant studies and developed recommendations for clinical practice. Based on the inclusion criteria, five systematic reviews and ten randomized controlled trials were included in the analysis. The recommendations include offering doublet chemotherapy or triplet therapy to previously untreated mCRC patients who are initially unresectable, based on studies of chemotherapy combined with anti-vascular endothelial growth factor antibodies. Pembrolizumab is recommended for first-line treatment of mCRC patients with microsatellite instability-high or deficient mismatch repair tumors. Chemotherapy and anti-epidermal growth factor receptor therapy are recommended for microsatellite stable or proficient mismatch repair left-sided treatment-naive RAS wild-type mCRC, while chemotherapy and anti-vascular endothelial growth factor therapy are recommended for microsatellite stable or proficient mismatch repair RAS wild-type right-sided mCRC. Encorafenib plus cetuximab is recommended for previously treated BRAF V600E-mutant mCRC patients who have progressed after one previous line of therapy. Other recommendations are provided for patients with colorectal peritoneal metastases, liver metastases, and candidates for potentially curative resection of liver metastases. Multidisciplinary team management and shared decision making are also recommended.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Neelima Denduluri, Mark R. Somerfield, Mariana Chavez-MacGregor, Amy H. Comander, Zoneddy Dayao, Andrea Eisen, Rachel A. Freedman, Ragisha Gopalakrishnan, Stephanie L. Graff, Michael J. Hassett, Tari A. King, Gary H. Lyman, Gillian Rice Maupin, Raquel Nunes, Cheryl L. Perkins, Melinda L. Telli, Maureen E. Trudeau, Antonio C. Wolff, Sharon H. Giordano
Summary: The study recommends offering 14 cycles of adjuvant T-DM1 to patients with HER2-positive breast cancer with pathologic invasive residual disease after standard preoperative chemotherapy and HER2-targeted therapy, based on the results of the KATHERINE trial.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Sharon H. Giordano, Sarah Temin, Sarat Chandarlapaty, Jennie R. Crews, Jeffrey J. Kirshner, Ian E. Krop, Nancy U. Lin, Debra A. Patt, Jane Perlmutter, Naren Ramakrishna, Nancy E. Davidson, Maria Alice B. Franzoi, Carey K. Anders, Aki Ikawa
Summary: The purpose of this study is to update guideline recommendations for systemic therapy in HER2-positive advanced breast cancer patients. Based on a systematic literature review, recommendations were made including the use of HER2-targeted therapy and evaluation on a case-by-case basis.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Antonio C. Wolff, Mark R. Somerfield, Mitchell Dowsett, M. Elizabeth H. Hammond, Daniel F. Hayes, Lisa M. McShane, Thomas J. Saphner, Patricia A. Spears, Kimberly H. Allison
Summary: This article is an update on the recommendations for HER2 testing in breast cancer, affirming the 2018 ASCO-CAP recommendations. The article emphasizes a new indication for trastuzumab deruxtecan when HER2 is not overexpressed or amplified, and provides best practice recommendations to distinguish IHC 0 and 1+.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Laura A. Huppert, Ozge Gumusay, Dame Idossa, Hope S. Rugo
Summary: HR-positive/HER2-negative breast cancer is characterized by the presence of estrogen receptor and/or progesterone receptor and the absence of HER2 gene amplification. It accounts for a significant proportion of breast cancers and is treated with endocrine therapy. Combining endocrine therapy with cyclin-dependent kinase inhibitors has shown promising results in reducing recurrence and improving survival. Chemotherapy is used based on the stage and tumor biology. New therapies, such as novel endocrine agents and antibody-drug conjugates, are changing the treatment landscape.
CA-A CANCER JOURNAL FOR CLINICIANS
(2023)
Article
Oncology
Rahul Seth, Hans Messersmith, Pauline Funchain
Summary: ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations in response to new and practice-changing data. Supported by evidence review and following the ASCO Guideline Methodology Manual, the goal of these updates is to disseminate timely recommendations to inform health practitioners and the public about the best available cancer care options.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Denise M. Wolf, Christina Yau, Julia Wulfkuhle, Lamorna Brown-Swigart, Rosa Gallagher, Pei Rong Evelyn Lee, Zelos Zhu, Mark J. Magbanua, Rosalyn Sayaman, Nicholas O'Grady, Amrita Basu, Amy Delson, Jean Philippe Coppe, Ruixiao Lu, Jerome Braun, Smita M. Asare, Laura Sit, Jeffrey B. Matthews, Jane Perlmutter, Nola Hylton, Minetta C. Liu, Paula Pohlmann, W. Fraser Symmans, Hope S. Rugo, Claudine Isaacs, Angela M. DeMichele, Douglas Yee, Donald A. Berry, Lajos Pusztai, Emanuel F. Petricoin, Gillian L. Hirst, Laura J. Esserman, Laura J. van 't Veer
Summary: By incorporating gene expression, protein/phosphoprotein, and clinical data, we have created new breast cancer subtypes that can better predict drug responses. The best performing subtypes include Immune, DNA repair, and HER2/Luminal phenotypes. Treatment allocation based on these subtypes significantly increases the overall pathologic complete response rate. This study is important for guiding future breast cancer treatment.
Article
Oncology
Massimo Cristofanilli, Hope S. Rugo, Seock-Ah Im, Dennis J. Slamon, Nadia Harbeck, Igor Bondarenko, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Hiroji Iwata, Ben O'Leary, Fabrice Andre, Sibylle Loibl, Eustratios Bananis, Yuan Liu, Xin Huang, Sindy Kim, Maria Jose Lechuga Frean, Nicholas C. Turner
Summary: This study conducted a long-term analysis of overall survival (OS) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. The results showed that treatment with palbociclib plus fulvestrant significantly improved survival compared to placebo plus fulvestrant, particularly in patients with endocrine-sensitive disease, no prior chemotherapy for advanced breast cancer, and low circulating tumor fraction.
CLINICAL CANCER RESEARCH
(2022)
Article
Medicine, General & Internal
J. Cortes, S. -B Kim, W. -P Chung, S. -A Im, Y. H. Park, R. Hegg, M. H. Kim, L. -M Tseng, V Petry, C. -F Chung, H. Iwata, E. Hamilton, G. Curigliano, B. Xu, C. -S Huang, J. H. Kim, J. W. Y. Chiu, J. L. Pedrini, C. Lee, Y. Liu, J. Cathcart, E. Bako, S. Verma, S. A. Hurvitz
Summary: Among patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane, trastuzumab deruxtecan was associated with a lower risk of disease progression or death compared to trastuzumab emtansine. However, treatment with trastuzumab deruxtecan was associated with interstitial lung disease and pneumonitis.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Oncology
Mark Jesus M. Magbanua, Ozge Gumusay, Razelle Kurzrock, Laura J. van't Veer, Hope S. Rugo
Summary: Liquid biopsy biomarkers, such as CTCs and ctDNA, are noninvasive diagnostics that can complement current predictive and prognostic tools in breast cancer treatment. They have been applied in evaluating immune therapy response and outcomes, with emerging technologies further advancing their applications.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Shanu Modi, William Jacot, Toshinari Yamashita, Joohyuk Sohn, Maria Vidal, Eriko Tokunaga, Junji Tsurutani, Naoto T. Ueno, Aleix Prat, Yee Soo Chae, Keun Seok Lee, Naoki Niikura, Yeon Hee Park, Binghe Xu, Xiaojia Wang, Miguel Gil-Gil, Wei Li, Jean-Yves Pierga, Seock-Ah Im, Halle C. F. Moore, Hope S. Rugo, Rinat Yerushalmi, Flora Zagouri, Andrea Gombos, Sung-Bae Kim, Qiang Liu, Ting Luo, Cristina Saura, Peter Schmid, Tao Sun, Dhiraj Gambhire, Lotus Yung, Yibin Wang, Jasmeet Singh, Patrik Vitazka, Gerold Meinhardt, Nadia Harbeck, David A. Cameron
Summary: Trastuzumab deruxtecan demonstrated significantly longer progression-free and overall survival compared to physician's choice chemotherapy in patients with HER2-low metastatic breast cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
J. Cortes, H. S. Rugo, D. W. Cescon, S-A Im, M. M. Yusof, C. Gallardo, O. Lipatov, C. H. Barrios, J. Perez-Garcia, H. Iwata, N. Masuda, M. Torregroza Otero, E. Gokmen, S. Loi, Z. Guo, X. Zhou, V Karantza, W. Pan, P. Schmid
Summary: The addition of pembrolizumab to chemotherapy significantly improves overall survival in patients with advanced triple-negative breast cancer whose tumors express PD-L1 with a CPS of 10 or more.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Multidisciplinary Sciences
Joyce Lee, Filomena Housley, Christina Yau, Rachel Nakagawa, Juliane Winkler, Johanna M. Anttila, Pauliina M. Munne, Mariel Savelius, Kathleen E. Houlahan, Daniel Van de Mark, Golzar Hemmati, Grace A. Hernandez, Yibing Zhang, Susan Samson, Carole Baas, Laura J. Esserman, Laura J. van 't Veer, Hope S. Rugo, Christina Curtis, Juha Klefstrom, Mehrdad Matloubian, Andrei Goga
Summary: This study reveals that TNBCs with elevated MYC expression are resistant to immune checkpoint inhibitor therapy, but this resistance can be overcome by restoring interferon signaling and targeting specific molecules. This finding has important implications for improving the outcomes of patients with TNBC treated with immune checkpoint inhibitors.
NATURE COMMUNICATIONS
(2022)
Review
Oncology
H. S. Rugo, G. Bianchini, J. Cortes, J-W Henning, M. Untch
Summary: This article discusses the management of common and special interest adverse events in patients with HER2-positive unresectable/metastatic breast cancer receiving T-DXd treatment. Prophylaxis for nausea and vomiting and proactive management of ILD/pneumonitis are highlighted as particularly important. Strategies for managing other T-DXd-related adverse events are also discussed.
Article
Oncology
Hope S. Rugo, Aditya Bardia, Frederik Marme, Javier Cortes, Peter Schmid, Delphine Loirat, Olivier Tredan, Eva Ciruelos, Florence Dalenc, Patricia Gomez Pardo, Komal L. Jhaveri, Rosemary Delaney, Olivia Fu, Lanjia Lin, Wendy Verret, Sara M. Tolaney
Summary: The study demonstrates the potential of Sacituzumab govitecan in the treatment of breast cancer, with a longer progression-free survival compared to traditional chemotherapy regimens and a manageable safety profile.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Mythili Shastry, Saya Jacob, Hope S. Rugo, Erika Hamilton
Summary: Antibody drug conjugates (ADCs) combine the cytotoxicity of chemotherapy and the targeted therapy of antibodies into a single molecule. TROP-2, a transmembrane glycoprotein, is expressed in multiple tumor types, especially in HER2-negative breast tumors, and is associated with worse survival. Sacituzumab govitecan (SG) is a first-in-class TROP-2-directed ADC that has shown significant improvement in progression-free survival and overall survival in pretreated metastatic triple-negative breast cancer. Datopotamab deruxtecan (Dato-DXd) is another TROP-2 ADC that has demonstrated preliminary efficacy in unselected metastatic TNBC. Both SG and Dato-DXd have the potential to deliver enhanced efficacy with reduced toxicity in breast cancer.
Correction
Multidisciplinary Sciences
Joyce V. Lee, Filomena Housley, Christina Yau, Rachel Nakagawa, Juliane Winkler, Johanna M. Anttila, Pauliina M. Munne, Mariel Savelius, Kathleen E. Houlahan, Daniel van de Mark, Golzar Hemmati, Grace A. Hernandez, Yibing Zhang, Susan Samson, Carole Baas, Marleen Kok, Laura J. Esserman, Laura J. van 't Veer, Hope S. Rugo, Christina Curtis, Juha Klefstrom, Mehrdad Matloubian, Andrei Goga
NATURE COMMUNICATIONS
(2022)
Review
Oncology
Laura A. Huppert, Ozge Gumusay, Dame Idossa, Hope S. Rugo
Summary: HR-positive/HER2-negative breast cancer is characterized by the presence of estrogen receptor and/or progesterone receptor and the absence of HER2 gene amplification. It accounts for a significant proportion of breast cancers and is treated with endocrine therapy. Combining endocrine therapy with cyclin-dependent kinase inhibitors has shown promising results in reducing recurrence and improving survival. Chemotherapy is used based on the stage and tumor biology. New therapies, such as novel endocrine agents and antibody-drug conjugates, are changing the treatment landscape.
CA-A CANCER JOURNAL FOR CLINICIANS
(2023)
Review
Oncology
Hope S. Rugo, Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M. Layman, Massimo Cristofanilli, Mylin A. Torres, Giuseppe Curigliano, Richard S. Finn, Angela DeMichele
Summary: This is a summary of an article about a study called P-REALITY X, which found that patients with metastatic HR+/HER2- breast cancer treated with palbociclib plus an AI lived longer than those treated with an AI only in routine clinical practice. These results support the use of palbociclib plus an AI as the standard first-line treatment for this type of breast cancer.
Review
Oncology
Stephen Johnston, Anna Emde, Carlos Barrios, Stefanie Srock, Patrick Neven, Miguel Martin, David Cameron, Wolfgang Janni, Michael Gnant
Summary: CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib have become standard-of-care therapy for hormone receptor-positive advanced or metastatic breast cancer, with improved progression-free survival and overall survival demonstrated in randomized trials. However, the results in early breast cancer are inconsistent. This review focuses on nonclinical studies investigating mechanistic differences, the impact of continuous dosing, and translational research into resistance mechanisms and prognostic markers, aiming to understand the similarities and differences between available CDK4/6 inhibitors.
JNCI CANCER SPECTRUM
(2023)
Article
Oncology
Hope S. S. Rugo, Victoria Harmer, Joyce O'Shaughnessy, Komal Jhaveri, Sara M. M. Tolaney, Fatima Cardoso, Aditya Bardia, Vikalp Kumar Maheshwari, Sandeep Tripathi, Sina Haftchenary, Purnima Pathak, Peter A. A. Fasching
Summary: This study compared patient-reported quality of life (QoL) between MONALEESA-2 (ribociclib + aromatase inhibitor) and MONARCH 3 (abemaciclib + aromatase inhibitor) treatments using a matching-adjusted indirect comparison (MAIC). The results showed that ribociclib + AI was associated with better symptom-related QoL compared to abemaciclib + AI.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)